Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial
IFNB Multiple Sclerosis Study Group - Neurology, 1993 - AAN Enterprises
We report a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-
lb (IFNB) in 372 ambulatory patients with relapsing-remitting multiple sclerosis (MS). Entry
criteria included an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and at least
two exacerbations in the previous 2 years. One-third of the patients received placebo, one-
third 1.6 million international units (MIU) of IFNB, and one-third 8 MIU of IFNB, self-
administered by subcutaneous injections every other day. The primary end points were …
lb (IFNB) in 372 ambulatory patients with relapsing-remitting multiple sclerosis (MS). Entry
criteria included an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and at least
two exacerbations in the previous 2 years. One-third of the patients received placebo, one-
third 1.6 million international units (MIU) of IFNB, and one-third 8 MIU of IFNB, self-
administered by subcutaneous injections every other day. The primary end points were …
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double‐blind, placebo‐controlled trial
DW Paty, DKB Li, Ubc MS/MRI Study Group… - neurology, 1993 - AAN Enterprises
We performed yearly MRI analyses on 327 of the total 372 patients in a multicenter,
randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB). Clinical
results are presented in the preceding companion paper. Baseline MRI characteristics were
the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent
MRIs (one every 6 weeks) for analysis of disease activity. The MRI results support the
clinical results in showing a significant reduction in disease activity as measured by …
randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB). Clinical
results are presented in the preceding companion paper. Baseline MRI characteristics were
the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent
MRIs (one every 6 weeks) for analysis of disease activity. The MRI results support the
clinical results in showing a significant reduction in disease activity as measured by …